WO2023133470A3 - Tmprss2 binding antibodies and antigen binding fragments thereof - Google Patents

Tmprss2 binding antibodies and antigen binding fragments thereof Download PDF

Info

Publication number
WO2023133470A3
WO2023133470A3 PCT/US2023/060179 US2023060179W WO2023133470A3 WO 2023133470 A3 WO2023133470 A3 WO 2023133470A3 US 2023060179 W US2023060179 W US 2023060179W WO 2023133470 A3 WO2023133470 A3 WO 2023133470A3
Authority
WO
WIPO (PCT)
Prior art keywords
tmprss2
antibodies
binding
antigen binding
fragments
Prior art date
Application number
PCT/US2023/060179
Other languages
French (fr)
Other versions
WO2023133470A2 (en
Inventor
Anagha DIVEKAR
Susannah KASSMER
Takatoku Oida
Original Assignee
BioLegend, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioLegend, Inc. filed Critical BioLegend, Inc.
Publication of WO2023133470A2 publication Critical patent/WO2023133470A2/en
Publication of WO2023133470A3 publication Critical patent/WO2023133470A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Abstract

Compositions and methods comprising TMPRSS2 binding antibodies and antigen binding fragments thereof are provided.
PCT/US2023/060179 2022-01-07 2023-01-05 Tmprss2 binding antibodies and antigen binding fragments thereof WO2023133470A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263297492P 2022-01-07 2022-01-07
US63/297,492 2022-01-07
US202263416370P 2022-10-14 2022-10-14
US63/416,370 2022-10-14

Publications (2)

Publication Number Publication Date
WO2023133470A2 WO2023133470A2 (en) 2023-07-13
WO2023133470A3 true WO2023133470A3 (en) 2023-08-24

Family

ID=87074288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060179 WO2023133470A2 (en) 2022-01-07 2023-01-05 Tmprss2 binding antibodies and antigen binding fragments thereof

Country Status (1)

Country Link
WO (1) WO2023133470A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150907A1 (en) * 2006-07-21 2010-06-17 Diadexus, Inc. Pro115 antibody compositions and methods of use
WO2011073954A2 (en) * 2009-12-18 2011-06-23 Sanofi-Aventis Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
WO2015032906A2 (en) * 2013-09-05 2015-03-12 Bionovion Holding B.V. Cd70-binding peptides and method, process and use relating thereto

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150907A1 (en) * 2006-07-21 2010-06-17 Diadexus, Inc. Pro115 antibody compositions and methods of use
WO2011073954A2 (en) * 2009-12-18 2011-06-23 Sanofi-Aventis Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
WO2015032906A2 (en) * 2013-09-05 2015-03-12 Bionovion Holding B.V. Cd70-binding peptides and method, process and use relating thereto

Also Published As

Publication number Publication date
WO2023133470A2 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
EP3990497A4 (en) Cd3 antigen binding fragments and compositions comprising same
MY194997A (en) Anti-ccr7 antibody drug conjugates
EP3928790A4 (en) Cd3 antigen binding fragment and application thereof
MX2022000325A (en) Dll3-targeting antibodies and uses thereof.
WO2021173896A8 (en) Materials and methods for modulating an immune response
WO2022132596A3 (en) Tissue-specific antigens for cancer immunotherapy
WO2022082073A3 (en) Compositions and methods for muc18 targeting
WO2021207948A9 (en) Anti-sars-cov-2 antibodies and uses thereof
WO2023114701A3 (en) Cd28 binding antibodies and antigen binding fragments thereof
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
WO2020123662A3 (en) Fusion protein constructs for complement associated disease
WO2022108976A3 (en) Anti-gpa33 multi-specific antibodies and uses thereof
MX2022016322A (en) High affinity antibodies targeting tau phosphorylated at serine 413.
MX2021006362A (en) Single domain antibodies against cll-1.
WO2022162518A3 (en) Psma binding proteins and uses thereof
CR20230245A (en) Gucy2c binding molecules and uses thereof
MX2023002948A (en) Methods and compositions for modulating beta chain mediated immunity.
WO2023133470A3 (en) Tmprss2 binding antibodies and antigen binding fragments thereof
MX2022003432A (en) Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability.
WO2021058711A3 (en) Antigen binding proteins
WO2021163562A3 (en) Compositions and methods comprising splicing-derived antigens for treating cancer
CR20230581A (en) Anti-ccr8 antibodies and uses thereof
AU2022242125A1 (en) Proteins comprising cd3 antigen binding domains and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23737754

Country of ref document: EP

Kind code of ref document: A2